General Information of the Disease (ID: DIS00122)
Name
Intervertebral disc degeneration
ICD
ICD-11: FA80
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
In total 6 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [1]
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Drug Hesperidin Approved
Responsed Regulator Transcription factor p65 (RELA) Driver
Pathway Response Fatty acid metabolism hsa01212
NF-kappa B signaling pathway hsa04064
Cell Process Cell ferroptosis
In Vitro Model hNPCs (Human nucleus pulposus cells)
In Vivo Model
Male C57BL/6 mice (10-12 weeks) were devoted to generate needle puncture-induced intervertebral disc degeneration model. For intervertebral disc degeneration (IVDD) treatment, hesperidin was administratedorally and the dose was calculated in reference to previous studies using themetrological conversion formula between human and mouse. The dosein mice is = 5.5 mg/kg x 70 kg x 0.0026/20g = 9.1 x 5.5 mg/kg = 50.05 mg/kg ~50 mg/kg.

    Click to Show/Hide
Response regulation The current study proved for the first time that Hesperidin may protect HNP cells from degeneration by suppressing ferroptosis in an oxidative stress-dependent via enhancing the expression of Nrf2 and suppressing the NF-kB pathway. The evidence will provide a possible basis for future targeted treatment for intervertebral disc degeneration.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [6]
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator Mitochondrial import inner membrane translocase subunit Tim9 (TIMM9) Driver
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model hNPCs (Human nucleus pulposus cells)
Response regulation Ferroptosis and immune infiltration play an important role in the pathogenesis of intervertebral disc degeneration (IDD). Seven key differentially expressed FRGs (DE-FRGs) were screened, including the upregulated genes NOX4 and PIR, and the downregulated genes TIMM9, ATF3, ENPP2, FADS2 and TFAP2A.
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target [7]
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator Early growth response protein 1 (EGR1) Driver
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
NF-kappa B signaling pathway hsa04064
Cell Process Cell ferroptosis
In Vitro Model hCEPs (Human cartilage endplate cells)
In Vivo Model
24 male C57BL/6J mice (8 weeks, weighing 20 ± 2 g) were purchased from Charles River (Beijing, China). Mice were anesthetized via an intraperitoneal injection of 3% pentobarbital sodium (40 mg/kg). Afterward, their extraperitoneal space was isolated and the exterior part of IVD was exposed. A 26 G puncture needle (90% of intervertebral space height) was utilized to punch in the C6/C7 IVD at a depth of 2.5 mm. The puncture needle was inserted into the dorsal annulus fibrosus across the center of the nucleus pulposus and partially across the ventral annulus fibrosus and withdrawn 30 s later.

    Click to Show/Hide
Response regulation In Intervertebral disc degeneration (IVDD) cell models, EGR1 knockdown reduced ferroptosis and cartilage degeneration, which was reversed by MAP3K14 overexpression or Erastin treatment. Collectively, EGR1 promoted ferroptosis and IVD cartilage degeneration through MAP3K14-NF-B axis.
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target [7]
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator Mitogen-activated protein kinase kinase kinase 14 (MAP3K14) Driver
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
NF-kappa B signaling pathway hsa04064
Cell Process Cell ferroptosis
In Vitro Model hCEPs (Human cartilage endplate cells)
In Vivo Model
24 male C57BL/6J mice (8 weeks, weighing 20 ± 2 g) were purchased from Charles River (Beijing, China). Mice were anesthetized via an intraperitoneal injection of 3% pentobarbital sodium (40 mg/kg). Afterward, their extraperitoneal space was isolated and the exterior part of IVD was exposed. A 26 G puncture needle (90% of intervertebral space height) was utilized to punch in the C6/C7 IVD at a depth of 2.5 mm. The puncture needle was inserted into the dorsal annulus fibrosus across the center of the nucleus pulposus and partially across the ventral annulus fibrosus and withdrawn 30 s later.

    Click to Show/Hide
Response regulation In Intervertebral disc degeneration (IVDD) cell models, EGR1 knockdown reduced ferroptosis and cartilage degeneration, which was reversed by MAP3K14 overexpression or Erastin treatment. Collectively, EGR1 promoted ferroptosis and IVD cartilage degeneration through MAP3K14-NF-B axis.
Experiment 5 Reporting the Ferroptosis-centered Disease Response by This Target [8]
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator Ubiquitin carboxyl-terminal hydrolase 11 (USP11) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Ubiquitin mediated proteolysis hsa04120
Cell Process Cell ferroptosis
In Vitro Model HEK-293T cells Normal Homo sapiens CVCL_0063
HNP (Human nucleus pulposus cells)
In Vivo Model
8-10 weeks old male mice were placed in prone position and anesthetized with isoflurane inhalation. The 1.5 cm-long longitudinal incision was made in 2 mm from the posterior midline. The superior and inferior articular processes, supraspinous ligament and interspinous ligament of the L4-L5 lumbar vertebrae were removed to construct LSI, which would induce IVDD. After the operation, the mice were placed in a warm environment.

    Click to Show/Hide
Response regulation Overexpression of USP11 significantly ameliorate oxidative stress-induced ferroptosis, thus relieving intervertebral disc degeneration (IVDD) by increasing Sirt3. Moreover, knockout of USP11 in vivo (USP11) resulted in exacerbated IVDD and poor pain-related behavioral scores, which could be reversed by overexpression of Sirt3 in intervertebral disc.
Experiment 6 Reporting the Ferroptosis-centered Disease Response by This Target [8]
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator NAD-dependent protein deacetylase sirtuin-3, mitochondrial (SIRT3) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Ubiquitin mediated proteolysis hsa04120
Cell Process Cell ferroptosis
In Vitro Model HEK-293T cells Normal Homo sapiens CVCL_0063
HNP (Human nucleus pulposus cells)
In Vivo Model
8-10 weeks old male mice were placed in prone position and anesthetized with isoflurane inhalation. The 1.5 cm-long longitudinal incision was made in 2 mm from the posterior midline. The superior and inferior articular processes, supraspinous ligament and interspinous ligament of the L4-L5 lumbar vertebrae were removed to construct LSI, which would induce IVDD. After the operation, the mice were placed in a warm environment.

    Click to Show/Hide
Response regulation Overexpression of USP11 significantly ameliorate oxidative stress-induced ferroptosis, thus relieving intervertebral disc degeneration (IVDD) by increasing Sirt3. Moreover, knockout of USP11 in vivo (USP11) resulted in exacerbated IVDD and poor pain-related behavioral scores, which could be reversed by overexpression of Sirt3 in intervertebral disc.
Transferrin receptor protein 2 (TFR2)
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [2]
Target for Ferroptosis Driver
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator Circ_STC2 (circRNA) Driver
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model hNPCs (Human nucleus pulposus cells)
Response regulation Circ-STC2 and TFR2 expressions were up-regulated in intervertebral disc degeneration (IDD) tissues, and miR-486-3p expression was down-regulated. Circ-STC2 inhibits the cell viability, induced the ferroptosis of the TBHP treated NPCs via targeting miR-486-3p/TFR2 axis.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [2]
Target for Ferroptosis Driver
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator hsa-miR-486-3p (miRNA) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model hNPCs (Human nucleus pulposus cells)
Response regulation Circ-STC2 and TFR2 expressions were up-regulated in intervertebral disc degeneration (IDD) tissues, and miR-486-3p expression was down-regulated. Circ-STC2 inhibits the cell viability, induced the ferroptosis of the TBHP treated NPCs via targeting miR-486-3p/TFR2 axis.
Solute carrier family 40 member 1 (SLC40A1)
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [3]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator hsa-miR-10a-5p (miRNA) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model hCDs (Chondrocytes)
Response regulation Inflammatory cytokine IL-6 appeared in Intervertebral disc degeneration (IDD) aggravates its degeneration by inducing cartilage cell ferroptosis. This is caused partially by inhibiting miR-10a-5p and subsequently derepressing IL-6R signaling pathway. The ferroptosis-inhibitory effect exhibited by overexpressing miR-10a-5p was achieved by promoting GPX4 and ferroportin-1 (FPN1) but suppressing divalent metal transporter 1 (DMT1) expression in IL-6-treated cartilage cells.
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 2 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [4]
Target for Ferroptosis Suppressor
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Drug L-Homocysteine Investigative
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Necroptosis hsa04217
Cell Process Cell ferroptosis
Cell apoptosis
Cell necrosis
In Vitro Model hNPCs (Human nucleus pulposus cells)
In Vivo Model
Thirty male C57BL/6 mice (8 weeks old, average weight 25 g) were divided into three groups. Blank group: Ten mice were fed with normal diet and water. HHcy group: Ten mice were fed with a high Met diet (normal diet with 2% l-methionine). HHcy + Folic Acidrescue group: Ten mice were fed withhigh Met diet (normal diet with 2% l-methionine), and injected with Folic Acid (1.0 umol/kg/d) twice a week two months later. At the beginning of treatment, mice were anesthetized with anintraperitoneal injectionof 0.3% (w/v)pentobarbital sodium(20 uL/g) before surgery and disc degeneration was induced by stabbing the C5-6 and C6-7 discs with a 32G needle.

    Click to Show/Hide
Response regulation Homocysteine (Hcy) is an amino acid involved in gene methylation. Hcy upregulates oxidative stress and ferroptosis in the nucleus pulposus via enhancing GPX4 methylation, and is a new contributing factor in intervertebral disc degeneration (IVDD).
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [3]
Target for Ferroptosis Suppressor
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator hsa-miR-10a-5p (miRNA) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model hCDs (Chondrocytes)
Response regulation Inflammatory cytokine IL-6 appeared in Intervertebral disc degeneration (IDD) aggravates its degeneration by inducing cartilage cell ferroptosis. This is caused partially by inhibiting miR-10a-5p and subsequently derepressing IL-6R signaling pathway. The ferroptosis-inhibitory effect exhibited by overexpressing miR-10a-5p was achieved by promoting GPX4 and ferroportin-1 (FPN1) but suppressing divalent metal transporter 1 (DMT1) expression in IL-6-treated cartilage cells.
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
In total 3 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Drug Hesperidin Approved
Pathway Response Fatty acid metabolism hsa01212
NF-kappa B signaling pathway hsa04064
Cell Process Cell ferroptosis
In Vitro Model hNPCs (Human nucleus pulposus cells)
In Vivo Model
Male C57BL/6 mice (10-12 weeks) were devoted to generate needle puncture-induced intervertebral disc degeneration model. For intervertebral disc degeneration (IVDD) treatment, hesperidin was administratedorally and the dose was calculated in reference to previous studies using themetrological conversion formula between human and mouse. The dosein mice is = 5.5 mg/kg x 70 kg x 0.0026/20g = 9.1 x 5.5 mg/kg = 50.05 mg/kg ~50 mg/kg.

    Click to Show/Hide
Response regulation Hesperidin may protect HNP cells from degeneration by suppressing ferroptosis in an oxidative stress-dependent via enhancing the expression of Nrf2 and suppressing the NF-B pathway. The evidence will provide a possible basis for future targeted treatment for intervertebral disc degeneration.
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target [5]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator Circ_0072464 (circRNA) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model hBMCs (Bone marrow cells)
hBMSCs (Bone marrow stromal cells)
Response regulation BMSC-EV-loaded circ_0072464 inhibited NPC ferroptosis to relieve intervertebral disc degeneration (IDD) via upregulation of miR-431-mediated NRF2, therefore providing a potential therapeutic target against IDD.
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target [5]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator hsa-miR-431-3p (miRNA) Driver
Pathway Response Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model hBMCs (Bone marrow cells)
hBMSCs (Bone marrow stromal cells)
Response regulation BMSC-EV-loaded circ_0072464 inhibited NPC ferroptosis to relieve intervertebral disc degeneration (IDD) via upregulation of miR-431-mediated NRF2, therefore providing a potential therapeutic target against IDD.
Natural resistance-associated macrophage protein 2 (SLC11A2)
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [3]
Target for Ferroptosis Driver
Responsed Disease Intervertebral disc degeneration [ICD-11: FA80]
Responsed Regulator hsa-miR-10a-5p (miRNA) Suppressor
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model hCDs (Chondrocytes)
Response regulation Inflammatory cytokine IL-6 appeared in Intervertebral disc degeneration (IDD) aggravates its degeneration by inducing cartilage cell ferroptosis. This is caused partially by inhibiting miR-10a-5p and subsequently derepressing IL-6R signaling pathway. The ferroptosis-inhibitory effect exhibited by overexpressing miR-10a-5p was achieved by promoting GPX4 and ferroportin-1 (FPN1) but suppressing divalent metal transporter 1 (DMT1) expression in IL-6-treated cartilage cells.
References
Ref 1 Hesperidin mitigates oxidative stress-induced ferroptosis in nucleus pulposus cells via Nrf2/NF-B axis to protect intervertebral disc from degeneration. Cell Cycle. 2023 May;22(10):1196-1214. doi: 10.1080/15384101.2023.2200291. Epub 2023 Apr 13.
Ref 2 Circ-STC2 promotes the ferroptosis of nucleus pulposus cells via targeting miR-486-3p/TFR2 axis. J Orthop Surg Res. 2023 Jul 21;18(1):518. doi: 10.1186/s13018-023-04010-1.
Ref 3 Targeting miR-10a-5p/IL-6R axis for reducing IL-6-induced cartilage cell ferroptosis. Exp Mol Pathol. 2021 Feb;118:104570. doi: 10.1016/j.yexmp.2020.104570. Epub 2020 Nov 7.
Ref 4 Homocysteine induces oxidative stress and ferroptosis of nucleus pulposus via enhancing methylation of GPX4. Free Radic Biol Med. 2020 Nov 20;160:552-565. doi: 10.1016/j.freeradbiomed.2020.08.029. Epub 2020 Sep 5.
Ref 5 circ_0072464 Shuttled by Bone Mesenchymal Stem Cell-Secreted Extracellular Vesicles Inhibits Nucleus Pulposus Cell Ferroptosis to Relieve Intervertebral Disc Degeneration. Oxid Med Cell Longev. 2022 Jun 29;2022:2948090. doi: 10.1155/2022/2948090. eCollection 2022.
Ref 6 Identifification and validation of ferroptosis signatures and immune infifiltration characteristics associated with intervertebral disc degeneration. Front Genet. 2023 Feb 22;14:1133615. doi: 10.3389/fgene.2023.1133615. eCollection 2023.
Ref 7 EGR1 knockdown confers protection against ferroptosis and ameliorates intervertebral disc cartilage degeneration by inactivating the MAP3K14/NF-B axis. Genomics. 2023 Jul 13;115(5):110683. doi: 10.1016/j.ygeno.2023.110683. Online ahead of print.
Ref 8 The deubiquitinase USP11 ameliorates intervertebral disc degeneration by regulating oxidative stress-induced ferroptosis via deubiquitinating and stabilizing Sirt3. Redox Biol. 2023 Jun;62:102707. doi: 10.1016/j.redox.2023.102707. Epub 2023 Apr 20.